Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. During 2016, Avacta has made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. Progress has been made in all three of its areas of therapeutic interest, with the announcement that Avacta has tied up with the Memorial Sloan Kettering Cancer Center to investigate Affimers in CAR-T cell immunotherapies.
02 Nov 2016
Immunotherapy advances: Affimers join CAR-T
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Immunotherapy advances: Affimers join CAR-T
Avacta Group PLC (AVCT:LON) | 49.8 0.4 1.5% | Mkt Cap: 174.4m
- Published:
02 Nov 2016 -
Author:
Martin Hall -
Pages:
4
Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. During 2016, Avacta has made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. Progress has been made in all three of its areas of therapeutic interest, with the announcement that Avacta has tied up with the Memorial Sloan Kettering Cancer Center to investigate Affimers in CAR-T cell immunotherapies.